Characteristics of Post-Marketing Studies and their Contribution to Post-Marketing Safety Measures in Japan-Reference-Cited by-同舟云学术

Characteristics of Post-Marketing Studies and their Contribution to Post-Marketing Safety Measures in Japan

Published:2014-02-12 Issue:2 Volume:28 Page:67-73
ISSN:1178-2595
Container-title:Pharmaceutical Medicine
language:en
Short-container-title:Pharm Med

Author:

Kanmuri Kazuhiro,Narukawa Mamoru

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology

Link

http://link.springer.com/content/pdf/10.1007/s40290-014-0046-6.pdf

Reference15 articles.

1. Routledge P. 150 years of pharmacovigilance. Lancet. 1998;351:1200–1. doi: 10.1016/S0140-6736(98)03148-1 .

2. Rogers AS. Adverse drug events: identification and attribution. Drug Intell Clin Pharm. 1987;21:915–20.

3. WHO Policy Perspectives on Medicines. Pharmacovigilance: ensuring the safe use of medicines—WHO Policy Perspectives on Medicines, No. 009, October 2004. http://apps.who.int/medicinedocs/pdf/s6164e/s6164e.pdf . Accessed 18 Oct 2013.

4. Directors of Safety Division Pharmaceutical and Food Safety Bureau, Ministry of Health, Labour and Welfare [MHLW] and Director of Evaluation and Licensing Division, Pharmaceutical and Food Safety Bureau, MHLW. Risk management plan guidance. http://www.pmda.go.jp/english/service/pdf/mhlw/PFSB-SD-0411-1_PFSB-ELD-0411-1.pdf . Accessed 18 Oct 2013.

5. Yoshioka K, Kosasayama A, Yoshida M, et al. Post marketing surveillance of 13 products: safety and effectiveness. Pharmacoepidemiol Drug Saf. 1999;8:31–43.

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Sponsor’s Perspective on the Contribution of Regulatory-Required Observational Post-Marketing Studies to Understanding Human Drug Product Benefit/Risk in Japan;Pharmaceutical Medicine;2024-03-31

2. Drug Safety Assessment and the MID-NET® (Japanese Medical Information Database Network);SpringerBriefs for Data Scientists and Innovators;2022

3. Clarifying the Discussion Points in New Drug Application Reviews for Approval in Japan by a Government Advisory Council;Therapeutic Innovation & Regulatory Science;2017-07

4. Characteristics of safety information obtained from postmarketing observational studies for re-examination in Japan;SpringerPlus;2016-06-27

5. 2. Agenda for the Sound and Effective Implementation of Risk Management Plan System ;Japanese Journal of Pharmacoepidemiology/Yakuzai ekigaku;2015